As a neuropharmacologist with seventeen years of proven achievement in industrial "drug hunting", Adrian personally participated in the identification and characterization of novel antipsychotics, antidepressants and analgesics at the Servier Research Institute (Paris, France; 1993-2002) and at Pierre Fabre Laboratories (Castres, France; 2002-2010). In 2010, he created an independent neuropharmacology consulting service (NeuroAct Communication) and then co-founded Neurolixis in 2011, a neuroscience-focused start-up, where he serves as Chief Scientific Officer. Adrian was awarded a B.Sc. in Biochemistry (1988) and a Ph.D. in Neuropharmacology (1992) at the University of Kent at Canterbury (U.K.). 

Adrian acquired detailed program management experience of multidisciplinary neuropharmacology research with particular emphasis on integrating molecular, neurochemical and behavioral pharmacology. Adrian also possesses extensive experience leading project teams including medicinal chemists, early ADMET and preclinical development partners. He built international collaborations with academic researchers and managed preparation of drug development and Due Diligence dossiers. 

Adrian has published numerous research reports in peer-reviewed journals (see Publications) and given symposia presentations to a wide variety of audiences (academic and industrial researchers, clinicians, students, etc.). Adrian has also co-authored patents describing novel chemical entities (NCEs) and serves on the Editorial Boards of the International Journal of Neuropsychopharmacology and of Frontiers in Neuropharmacology. He is bi-national (anglo-italian) and tri-lingual (English, French, Italian).

For recommendations of Adrian's management skills and scientific competence see Endorsements.